2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 084

Early Life Exposures and Risk of Spondyloarthritis: A Population-Based Case-Control Study
Abstract Number: 125

Educational Interventions to Increase Transition Preparedness in a Pediatric Rheumatology Clinic
Abstract Number: 019

Effects of Childhood-Onset Interferon-Driven Autoimmune Disorders on Brain Volume and Executive Function: A Pilot Analysis in JDM and Childhood-Onset SLE
Abstract Number: 010

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)
Abstract Number: 044

Efficacy of Rituximab Biosimilars in Pediatric ANCA-Associated Vasculitis
Abstract Number: 070

Empowering Voices: Inception of a Parent Led Anatomical Visual Pain Assessment Tool for Juvenile Arthritis
Abstract Number: 097

Evaluating Associations between Diffusion Tensor Imaging Metrics and Cognitive Function in Youth with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Abstract Number: 062

Evaluating the Relationship Between an Electronic Transition Planning Tool and Transition Success in a Pediatric Rheumatology Clinic
Abstract Number: 119

Expansion of Mental Health Screening to Patients with Diverse Rheumatologic Diagnoses in an Outpatient Pediatric Rheumatology Clinic
Abstract Number: 080

Expansion of Type I IFN-driven ISGhigh Monocytes and Identification of MAS-Associated CD8+ T cell Population During Macrophage Activation Syndrome
Abstract Number: 100

Experience with Janus Kinase Inhibitors and Abatacept in Juvenile Dermatomyositis: A Retrospective Study from a Large Tertiary Center

Jump to: View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].